Reducing the burden with ApoE2

Gene Therapy

Volumn 12, Issue 13, 2005, Pages 1019-1020

  Federoff, Howard J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ENHANCED GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; PRESENILIN 1;

ALZHEIMER DISEASE; CELL LOSS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HIPPOCAMPUS; HUMAN; NERVE CELL; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SENILE PLAQUE; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; METABOLISM; MOUSE;

LENTIVIRUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E2; DISEASE MODELS, ANIMAL; GENE THERAPY; MICE;

EID: 21744440561     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302522     Document Type: Note

References (9)

1. Dodart JC et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2005; 102: 1211-1216.
2. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-685.
3. Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol Sci 2004; 25: 92-97.
4. Klein WL. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41: 345-352.
5. Lacor PN et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24: 10191-10200.
6. Cleary JP et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
7. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004; 63: 1155-1162.
8. Roses AD. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease. Neurobiol Aging 1994; 15 (Suppl 2): S165-S167.
9. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994; 53: 429-437.